Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. INTC
2. SPCX
3. DSX
4. GNK
5. SAN
6. TTEC
7. SNY
8. DAL
9. AWK
10. MDA

Go back to Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
(NASDAQ: SLDB) Delayed: 8.33 +1.02 (13.95%)
Previous Close $7.31    52 Week High $ 
Open $7.58    52 Week Low $ 
Day High $8.42    P/E N/A 
Day Low $7.49    EPS $ 
Volume 14,768,088